UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 104

Sortiert nach

Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors

Annals of oncology, 2006-04, Vol.17 (4), p.584-587

2006

Volltextzugriff (PDF)

Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance

Oncogene, 2010-08, Vol.29 (33), p.4648-4657

2010

Volltextzugriff (PDF)

Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics

JNCI : Journal of the National Cancer Institute, 2008-10, Vol.100 (19), p.1380-1388

2008

Volltextzugriff (PDF)

Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status

Annals of oncology, 2006-05, Vol.17 (5), p.818-826

2006

Volltextzugriff (PDF)

Assessment of the contribution of the IHC4 + C score to decision making in clinical practice in early breast cancer

British journal of cancer, 2012-05, Vol.106 (11), p.1760-1765

2012

Volltextzugriff (PDF)

Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC)

Annals of oncology, 2009-12, Vol.20 (12), p.1948-1952

2009

Volltextzugriff (PDF)

Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies

British journal of cancer, 2011-08, Vol.105 (5), p.709-722

HORMONES, Endogenous

2011

Volltextzugriff (PDF)

The AURORA initiative for metastatic breast cancer

British journal of cancer, 2014-11, Vol.111 (10), p.1881-1887

2014

Volltextzugriff (PDF)

Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer

Annals of oncology, 2014-03, Vol.25 (3), p.605-610

2014

Volltextzugriff (PDF)

Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

British journal of cancer, 2004-05, Vol.90 (12), p.2317-2325

2004

Volltextzugriff (PDF)

Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer

British journal of cancer, 2014-06, Vol.110 (12), p.2847-2854

2014

Volltextzugriff (PDF)

Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?

British journal of cancer, 2006-09, Vol.95 (6), p.661-666

2006

Volltextzugriff (PDF)

Polymorphisms Associated With Circulating Sex Hormone Levels in Postmenopausal Women

JNCI : Journal of the National Cancer Institute, 2004-06, Vol.96 (12), p.936-945

2004

Volltextzugriff (PDF)

Combined effects of endogenous sex hormone levels and mammographic density on postmenopausal breast cancer risk: results from the Breakthrough Generations Study

British journal of cancer, 2014-04, Vol.110 (7), p.1898-1907

2014

Volltextzugriff (PDF)

Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer

Annals of oncology, 2013-01, Vol.24 (1), p.126-133

2013

Volltextzugriff (PDF)

Endogenous Sex Hormones and Breast Cancer in Postmenopausal Women: Reanalysis of Nine Prospective Studies

JNCI : Journal of the National Cancer Institute, 2002-04, Vol.94 (8), p.606-616

2002

Volltextzugriff (PDF)

HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab

Annals of oncology, 2013-11, Vol.24 (11), p.2761-2766

2013

Volltextzugriff (PDF)

Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer

Annals of oncology, 2011-08, Vol.22 (8), p.1770-1776

2011

Volltextzugriff (PDF)

Proliferation Marker Ki-67 in Early Breast Cancer

Journal of clinical oncology, 2005-10, Vol.23 (28), p.7212-7220

2005

Volltextzugriff (PDF)

An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition

Steroids, 2011-07, Vol.76 (8), p.772-776

2011

Volltextzugriff (PDF)

EGFR HER2 inhibitor AEE788 increases ER-mediated transcription in HER2 ER-positive breast cancer cells but functions synergistically with endocrine therapy

British journal of cancer, 2010-04, Vol.102 (8), p.1235-1243

2010

Volltextzugriff (PDF)

Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy

British journal of cancer, 2007-01, Vol.96 (2), p.341-351

2007

Volltextzugriff (PDF)

Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials

The Lancet (British edition), 2014-06, Vol.383 (9935), p.2127-2135

2014

Volltextzugriff (PDF)

Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial

Annals of oncology, 2005-10, Vol.16 (10), p.1632-1638

2005

Volltextzugriff (PDF)

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

The Lancet (British edition), 2012-02, Vol.379 (9814), p.432-444

2012

Volltextzugriff (PDF)

1 – 25 von 104

Suche als RSS-Feed

Aktive Filter

ThemaGynecology. Andrology. Obstetrics

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(104)
Mit Volltextzugriff
(100)

Publikationsform

Artikel
(104)

Sprache

Englisch
(104)
Japanisch
(17)

Erscheinungsjahr

n.n

Thema

Biological And Medical Sciences
(104)
Medical Sciences
(104)
Tumors
(100)
Humans
(98)
Mammary Gland Diseases
(97)
Life Sciences & Biomedicine
(96)
Science & Technology
(96)
Female
(93)
Oncology
(72)
Breast Cancer
(52)
Middle Aged
(52)
Breast Neoplasms - Drug Therapy
(47)
Aged
(39)
Adult
(31)
Breast Neoplasms - Pathology
(29)
Breast Neoplasms - Metabolism
(25)
Antineoplastic Agents, Hormonal - Therapeutic Use
(22)
Pharmacology. Drug Treatments
(22)
Breast Neoplasms - Genetics
(21)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors

Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance

Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics

Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status

Assessment of the contribution of the IHC4 + C score to decision making in clinical practice in early breast cancer

Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC)

Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies

The AURORA initiative for metastatic breast cancer

Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer

Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer

Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?

Polymorphisms Associated With Circulating Sex Hormone Levels in Postmenopausal Women

Combined effects of endogenous sex hormone levels and mammographic density on postmenopausal breast cancer risk: results from the Breakthrough Generations Study

Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer

Endogenous Sex Hormones and Breast Cancer in Postmenopausal Women: Reanalysis of Nine Prospective Studies

HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab

Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer

Proliferation Marker Ki-67 in Early Breast Cancer

An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition

EGFR HER2 inhibitor AEE788 increases ER-mediated transcription in HER2 ER-positive breast cancer cells but functions synergistically with endocrine therapy

Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy

Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials

Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

Aktive Filter

Suchergebnisse filtern